Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Apellis Pharmaceuticals Inc before investing.

In this article, we go over a few key elements for understanding Apellis Pharmaceuticals Inc’s stock price such as:

• Apellis Pharmaceuticals Inc’s current stock price and volume
• Why Apellis Pharmaceuticals Inc’s stock price changed recently
• Upgrades and downgrades for APLS from analysts
• APLS’s stock price momentum as measured by its relative strength

About Apellis Pharmaceuticals Inc (APLS)

Before we jump into Apellis Pharmaceuticals Inc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.

Want to learn more about Apellis Pharmaceuticals Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Apellis Pharmaceuticals Inc.

Apellis Pharmaceuticals Inc’s Stock Price as of Market Close

As of June 28, 2024, 4:00 PM, CST, Apellis Pharmaceuticals Inc’s stock price was $38.36.

Apellis Pharmaceuticals Inc is down 7.61% from its previous closing price of $41.52.

During the last market session, Apellis Pharmaceuticals Inc’s stock traded between $39.90 and $41.61. Currently, there are 122.96 million shares of Apellis Pharmaceuticals Inc stock available for purchase.

Unfortunately, Apellis Pharmaceuticals Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Apellis Pharmaceuticals Inc Stock Price History

Apellis Pharmaceuticals Inc’s (APLS) price is currently down 2.27% so far this month.

During the month of June, Apellis Pharmaceuticals Inc’s stock price has reached a high of $43.76 and a low of $37.00.

Over the last year, Apellis Pharmaceuticals Inc has hit prices as high as $92.61 and as low as $19.83. Year to date, Apellis Pharmaceuticals Inc’s stock is down 25.82%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Apellis Pharmaceuticals Inc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 27, 2024, there were 0 analysts who downgraded Apellis Pharmaceuticals Inc’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Apellis Pharmaceuticals Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Apellis Pharmaceuticals Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Apellis Pharmaceuticals Inc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Apellis Pharmaceuticals Inc (APLS) by visiting AAII Stock Evaluator.

Relative Price Strength of Apellis Pharmaceuticals Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 27, 2024, Apellis Pharmaceuticals Inc has a weighted four-quarter relative price strength of -18.36%, which translates to a Momentum Score of 21 and is considered to be Weak.

Want to learn more about how Apellis Pharmaceuticals Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Apellis Pharmaceuticals Inc Stock Price: Bottom Line

As of June 28, 2024, Apellis Pharmaceuticals Inc’s stock price is $38.36, which is down 7.61% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Apellis Pharmaceuticals Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.